William E Fitzsimmons
Last and corresponding author of the 2026 GeroScience registry study of rapamycin and survival in kidney transplant recipients.
University of Illinois Chicago
William E Fitzsimmons is last author of STE2026, which compared 4,885 kidney transplant recipients prescribed rapamycin with 6,589 who were not, followed for a median of 11 years. The adjusted median survival ages were nearly identical.
In PubMed he is listed at the Colleges of Pharmacy and Medicine of the University of Illinois Chicago.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Rapamycin and human longevity among kidney transplant recipients surviving the first year. STE2026 Last author. No meaningful survival benefit from chronic rapamycin in this transplant cohort. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with William E Fitzsimmons.
ShowHide
- Darren E Stewart First author of the 2026 GeroScience registry study of rapamycin and survival in kidney transplant recipients.
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.